About AlphaCognition
AlphaCognition is a company based in Vancouver (Canada) founded in 2000. AlphaCognition offers products and services including ZUNVEYL. AlphaCognition operates in a competitive market with competitors including T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others.
- Headquarter Vancouver, Canada
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alpha Cognition Inc.
-
Annual Revenue
Not available
-
Net Profit
-$14.64 M (USD)-6.28as on Dec 31, 2024
-
EBITDA
-$11.83 M (USD)-20.84as on Dec 31, 2024
-
Latest Funding Round
$4.55 M (USD), Post-IPO
Sep 24, 2024
-
Investors
Manchester Capital Management
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AlphaCognition
AlphaCognition is a publicly listed company on the NASDAQ with ticker symbol ACOG in USA, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AlphaCognition
AlphaCognition offers a comprehensive portfolio of products and services, including ZUNVEYL.
Cholinesterase inhibitor for treating mild to moderate Alzheimer's disease in adults.
People of AlphaCognition
Unlock access to complete
Funding Insights of AlphaCognition
Investors in AlphaCognition
AlphaCognition has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Manchester Capital Management and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked | |
|
Multi-family office services are provided for wealth management.
|
Locked | Locked | Locked |
Investor details for AlphaCognition
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AlphaCognition
Investment portfolio details for AlphaCognition
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AlphaCognition
Detailed financials for AlphaCognition
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alphacognition Comparisons
Peer comparison for AlphaCognition
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AlphaCognition
AlphaCognition operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| Locked | Locked | Locked |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| Locked | Locked | Locked |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| Locked | Locked | Locked |
Medical foods and drugs for Alzheimer's disease are developed.
|
|
| Locked | Locked | Locked |
Genome-scale drug discovery platform is provided for treating multiple diseases.
|
Detailed competitors of AlphaCognition
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alphacognition
Complete news archive for AlphaCognition
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AlphaCognition
AlphaCognition was founded in 2000 and raised its 1st funding round 20 years after it was founded.
AlphaCognition is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Michael Mcfadden is the current CEO of AlphaCognition.
AlphaCognition was founded in 2000 in Vancouver, Canada, within the biotechnology sector. Focus is placed on developing therapeutics for neurological disorders affecting the brain and spinal cord. A patented chemical entity known as Alpha-1062, functioning as an acetylcholine esterase inhibitor, has been advanced for Alzheimers disease treatment, with human trials completed. Additionally, Alpha-602 has been created to address ALS.
AlphaCognition's top competitors include Alzheon, Longeveron and Alchemab.
AlphaCognition offers ZUNVEYL.
Yes, AlphaCognition is publicly traded on NASDAQ under the ticker symbol ACOG.
AlphaCognition has 2 investors. Key investors include Manchester Capital Management, and Military Health.
The ticker symbol of AlphaCognition is ACOG on NASDAQ.